First Patient Dosed in Phase 2b/3 Study of TD-1473 for Ulcerative Colitis

First Patient Dosed in Phase 2b/3 Study of TD-1473 for Ulcerative Colitis
Theravance Biopharma announced that the first patient has been dosed in a Phase 2b/3 study to test the efficacy and safety of its candidate oral drug TD-1473 for the treatment of moderate to severe active ulcerative colitis. The Phase 2b/3 clinical trial (
Subscribe or to access all post and page content.